» Articles » PMID: 16946130

Cholesteryl Ester Transfer Protein Decreases High-density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice

Overview
Date 2006 Sep 2
PMID 16946130
Citations 99
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The role of cholesteryl ester transfer protein (CETP) in the development of atherosclerosis is still undergoing debate. Therefore, we evaluated the effect of human CETP expression on atherosclerosis in APOE*3-Leiden (E3L) mice with a humanized lipoprotein profile.

Methods And Results: E3L mice were crossbred with human CETP transgenic mice. On a chow diet, CETP expression increased plasma total cholesterol (TC) (+43%; P<0.05). To evaluate the effects of CETP on the development of atherosclerosis, mice were fed a Western-type diet containing 0.25% cholesterol, leading to 4.3-fold elevated TC levels in both E3L and CETP.E3L mice (P<0.01). On both diets, CETP expression shifted the distribution of cholesterol from high-density lipoprotein (HDL) toward very-low-density lipoprotein (VLDL)/low-density lipoprotein (LDL). Moreover, plasma of CETP.E3L mice had reduced capacity (-39%; P<0.05) to induce SR-BI-mediated cholesterol efflux from Fu5AH cells than plasma of E3L mice. After 19 weeks on the Western-type diet, CETP.E3L mice showed a 7.0-fold increased atherosclerotic lesion area in the aortic root compared with E3L mice (P<0.0001).

Conclusions: CETP expression in E3L mice shifts the distribution of cholesterol from HDL to VLDL/LDL, reduces plasma-mediated SR-BI-dependent cholesterol efflux, and represents a clear pro-atherogenic factor in E3L mice. We anticipate that the CETP.E3L mouse will be a valuable model for the preclinical evaluation of HDL-raising interventions on atherosclerosis development.

Citing Articles

Butyrate Prevents Obesity Accompanied by HDAC9-Mediated Browning of White Adipose Tissue.

Yang J, Li G, Wang S, He M, Dong S, Wang T Biomedicines. 2025; 13(2).

PMID: 40002674 PMC: 11852213. DOI: 10.3390/biomedicines13020260.


Associations Between Gene Variants of Lipid-Lowering Drug Targets and Adverse Outcomes After Ischemic Stroke.

Sun L, Zhang Q, Shi M, Liu Y, Zhu Z, Zhang J J Am Heart Assoc. 2024; 13(22):e036544.

PMID: 39547981 PMC: 11681404. DOI: 10.1161/JAHA.124.036544.


Therapeutic effects of FGF21 mimetic bFKB1 on MASH and atherosclerosis in Ldlr-/-.Leiden mice.

Inia J, Attema J, de Ruiter C, Menke A, Caspers M, Verschuren L FASEB J. 2024; 38(20):e70087.

PMID: 39463193 PMC: 11580715. DOI: 10.1096/fj.202401397R.


Anti-Inflammatory Oxysterol, Oxy210, Inhibits Atherosclerosis in Hyperlipidemic Mice and Inflammatory Responses of Vascular Cells.

Stappenbeck F, Wang F, Sinha S, Hui S, Farahi L, Mukhamedova N Cells. 2024; 13(19).

PMID: 39404395 PMC: 11475996. DOI: 10.3390/cells13191632.


Liver-targeted Angptl4 silencing by antisense oligonucleotide treatment attenuates hyperlipidaemia and atherosclerosis development in APOE*3-Leiden.CETP mice.

Modder M, In Het Panhuis W, Li M, Afkir S, Dorn A, Pronk A Cardiovasc Res. 2024; 120(17):2179-2190.

PMID: 39259836 PMC: 11687395. DOI: 10.1093/cvr/cvae195.